Steve Greene(@SJGreene_md) 's Twitter Profileg
Steve Greene

@SJGreene_md

Cardiologist at @DukeHeartCenter & @DCRINews | Podcast: #DontMissABeat | Views & tweets are my own

ID:950586157364064256

linkhttps://medicine.duke.edu/faculty/stephen-greene-md calendar_today09-01-2018 04:32:55

4,0K Tweets

2,8K Followers

153 Following

Heart in Diabetes πŸ«€(@HeartinDiabetes) 's Twitter Profile Photo

Learn about DCRM 2.0 - Multi-Specialty Practice Recommendations for DM, Cardiorenal, & Metabolic Disease. Simultaneously presented at and published at the Journal Metabolism.

Steve Greene Erin D. Michos, M.D. Javed Butler

Learn about DCRM 2.0 - Multi-Specialty Practice Recommendations for DM, Cardiorenal, & Metabolic Disease. Simultaneously presented at #8HID and published at the Journal Metabolism. #HID24 #CME #CKM #8thHeartinDiabetes #MedEd #HID2024 @SJGreene_md @ErinMichos @JavedButler1
account_circle
Steve Greene(@SJGreene_md) 's Twitter Profile Photo

Terrific work led by Duke Cardiology Fellows Mark Kittipibul MD

Many πŸ₯ and patients continue to struggle w readmissions.

Across , significantly reduce both HF and **all-cause** hospitalization, regardless of EF

πŸ”—jacc.org/doi/10.1016/j.…

Duke Clinical Research Institute Muthu Vaduganathan

account_circle
Brendon Neuen(@brendonneuen) 's Twitter Profile Photo

Hot on the heels of FLOW:

What are the effects of SGLT2i on clinical outcomes with and without GLP-1RA? 🧡

Over 3,000 patients receiving GLP-1RA at baseline in SGLT2i Trialists' Consortium (SMART-C)

ERA - European Renal Association

Hot on the heels of FLOW: What are the effects of SGLT2i on clinical outcomes with and without GLP-1RA? 🧡 Over 3,000 patients receiving GLP-1RA at baseline in SGLT2i Trialists' Consortium (SMART-C) #ERA24 @ERAkidney
account_circle
Swapnil Hiremath @hswapnil@bsky.social(@hswapnil) 's Twitter Profile Photo

The FLOW trial results are live at @nejm as well



nejm.org/doi/full/10.10…

Primary composite kidney βœ…
CV Deathβœ…
All cause death βœ…
GFR slope βœ…
First MACE βœ…
Kidney specific composite βœ…

The FLOW trial results are live at @nejm as well #ERA24 nejm.org/doi/full/10.10… Primary composite kidney βœ… CV Deathβœ… All cause death βœ… GFR slope βœ… First MACE βœ… Kidney specific composite βœ…
account_circle
Brendon Neuen(@brendonneuen) 's Twitter Profile Photo

Effects of semaglutide on CV outcomes in FLOW presented by Kenneth Mahaffey

18% reduction in MACE

20% reduction in all cause mortality

NNT 39 to prevent one death over 3 years

ERA - European Renal Association

Effects of semaglutide on CV outcomes in FLOW presented by @TheMahaf 18% reduction in MACE 20% reduction in all cause mortality NNT 39 to prevent one death over 3 years #erakidney @ERAkidney
account_circle
Ahmed Bennis(@drbennisahmed) 's Twitter Profile Photo

Efficacy and Safety of Dapagliflozin in Patients With Acute HeartΒ Failure

Early dapagliflozin during AHF hospitalization is safe and fulfills a component of GDMT optimization.

Dapagliflozin associated with enhanced diuresis among patients with AHF

sciencedirect.com/science/articl…

Efficacy and Safety of Dapagliflozin in Patients With Acute HeartΒ Failure Early dapagliflozin during AHF hospitalization is safe and fulfills a component of GDMT optimization. Dapagliflozin associated with enhanced diuresis among patients with AHF sciencedirect.com/science/articl…
account_circle
Edgar V. Lerma πŸ‡΅πŸ‡­(@edgarvlermamd) 's Twitter Profile Photo

RENAL LIFECYCLE Trial: Efficacy and safety of dapagliflozin 10 mg vs placebo

βœ… eGFR <25
βœ… Patients on dialysis with residual diuresis >500 mL/24-hour
βœ… Kidney transplant recipients with an eGFR </=45

πŸ“Œ PRIMARY ENDPOINT: Composite end point of kidney

RENAL LIFECYCLE Trial: Efficacy and safety of dapagliflozin 10 mg vs placebo #Nephpearls #NephJC βœ… eGFR <25 βœ… Patients on dialysis with residual diuresis >500 mL/24-hour βœ… Kidney transplant recipients with an eGFR </=45 πŸ“Œ PRIMARY ENDPOINT: Composite end point of kidney
account_circle
Ahmed Bennis(@drbennisahmed) 's Twitter Profile Photo

Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure:
A pre-specified analysis from the from the SELECT trial

The demonstrated benefits of semaglutide were not different in HFpEF compared to HFrEE

Muthu Vaduganathan

Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the from the SELECT trial The demonstrated benefits of semaglutide were not different in HFpEF compared to HFrEE @mvaduganathan
account_circle
Muthu Vaduganathan(@mvaduganathan) 's Twitter Profile Photo

The Inflation Reduction Act and Access to Heart Failure Therapies - Prices, Progress, and Promise

New informative Journal of Cardiac Failure Ignite πŸ”₯by leaders Andrew Oseran, MD MBA & Rishi Wadhera, MD MPP

onlinejcf.com/article/S1071-…

account_circle
Ahmed Bennis(@drbennisahmed) 's Twitter Profile Photo

Renal Compression in Heart Failure: The Renal Tamponade Hypothesis

The rigidness of the renal capsule is central in congestion-induced damage to the renal structures

Renal decapsulation has been shown to be beneficial in animals

jacc.org/doi/10.1016/j.…
Steve Greene

Renal Compression in Heart Failure: The Renal Tamponade Hypothesis The rigidness of the renal capsule is central in congestion-induced damage to the renal structures Renal decapsulation has been shown to be beneficial in animals jacc.org/doi/10.1016/j.… @SJGreene_md
account_circle
Ahmed Bennis(@drbennisahmed) 's Twitter Profile Photo



10 messages to remember from HFA 2024

Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure:

Message 5: Semaglutide reduced the risk of MACE and HF composite in HFrEF and HFpEF

#HeartFailure2024 10 messages to remember from HFA 2024 Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: Message 5: Semaglutide reduced the risk of MACE and HF composite in HFrEF and HFpEF
account_circle
Ahmed Bennis(@drbennisahmed) 's Twitter Profile Photo

Nurse-Led Diuretic Titration via
POC Urinary Sodium Sensor in
ADHF: EASY-HF trial

Significant improvement in natriuresis and diuresis after 48h, without an increased incidence in adverse events

Wilfried Mullens Steve Greene

Nurse-Led Diuretic Titration via POC Urinary Sodium Sensor in ADHF: EASY-HF trial Significant improvement in natriuresis and diuresis after 48h, without an increased incidence in adverse events @WilfriedMullens @SJGreene_md
account_circle